Combination of an NMDA receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders

Details for Australian Patent Application No. 2004251636 (hide)

Owner Forest Laboratories, Inc.

Inventors Gupta, Sandeep; Samoriski, Gary

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-B-2004251636

PCT Pub. Number WO2005/000216

Priority 60/473,639 27.05.03 US

Filing date 27 May 2004

Wipo publication date 6 January 2005

Acceptance publication date 9 November 2006

International Classifications

A61K 31/551 (2006.01) - having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep

Event Publications

8 December 2005 PCT application entered the National Phase

  PCT publication WO2005/000216 Priority application(s): WO2005/000216

9 November 2006 Application Accepted

  Published as AU-B-2004251636

8 March 2007 Standard Patent Sealed

24 March 2011 Assignment Registered

  Forest Laboratories, Inc. The patent has been assigned to Merz Pharma GmbH & CO. KGAA

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004251638-Methods of making plants that exhibit enhanced disease resistance

2004251635-Method of reducing the harmful effects of orally or transdermally delivered nicotine